Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356683 | 0.98 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL234550 | 0.98 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL16180769 | 0.96 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL5330004 | 0.88 | ESR1 (0.36) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4744273 | 0.84 | CYP3A4 (0.31) | CYP3A4TDP1 | |
| SCHEMBL1443600 | 0.84 | CYP2A6 (0.35) | TDP1 | |
| SCHEMBL900597 | 0.81 | — | — | |
| SCHEMBL1460886 | 0.80 | CYP2A6 (0.35) | CYP3A4TDP1 | |
| SCHEMBL3632076 | 0.80 | HSD17B2 (0.33) | — | |
| SCHEMBL8913546 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261891-A1 | COMPOSITIONS AND METHODS FOR USING SYRINGOPEPTIN 25A AND RHAMNOLIPIDS | UTAH STATE UNIVERSITY (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1896444-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4 , 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES | MARS, INCORPORATED (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005248-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF PROTECTED -(+)-CATECHIN AND (-)-EPICATECHIN NOMOMERS, FOR COUPLING THE PROTECTED MONOMERS WITH AN ACTIVATED, PROTECTED EPICATECHIN MONOMER, AND FOR THE PREPARATION OF EPICATECHIN-(4β, 8)-EPICATECHIN OR -CATECHIN DIMERS AND THEIR DIGALLATES | MARS, INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261891-A1 | COMPOSITIONS AND METHODS FOR USING SYRINGOPEPTIN 25A AND RHAMNOLIPIDS | CHIA, SGPL1, RPS25 | CYP3A4 4255/4885TDP1 4286/4885ESR1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.